UK NHS Carbon Reduction Plan

Supplier name: Bristol Myers Squibb

Publication date: August 2026

Commitment to achieving Net Zero

Bristol Myers Squibb is committed to reaching net-zero greenhouse gas (GHG) emissions across our value chain by 2050 and this commitment is supported and adopted by Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Pharmaceuticals Limited, Celgene Europe Limited, and Celgene Receptos (collectively, BMS UK). This goal was approved by the Science Based Target initiative (SBTi) in 2024. The information and data contained in this report relates to Bristol-Myers Squibb Company globally, of which BMS UK are wholly owned subsidiaries. The environmental measures stated herein are able to be applied by BMS UK when performing any relevant contracts.

Baseline Emissions Footprint

Details relating to the Emission Calculations
BMS follows the GHG Protocol to measure our combined enterprise GHG emissions for our Scope 1, Scope 2 and 10 relevant Scope 3 categories of and has the data externally verified with limited assurance. BMS uses the Operational Control Approach as defined in chapter 3 of the GHG Protocol Corporate Standard. Operational control is considered to exist where BMS, or one of its subsidiaries, has the authority to introduce and implement operating policies at the relevant operation. This operational-control is applied consistently to Scope 1, Scope 2, Scope 3, energy, water and waste inventories. We conduct ongoing analysis of our environmental data to ensure alignment with our established standards of data excellence, as well as regulatory bodies and frameworks. In 2025, this process resulted in the restatement of our 2022 baseline emissions to account for portfolio divestitures, an expanded reporting boundary, and revised methodologies associated with the implementation of a new carbon accounting tool.

GHG Emissions	Baseline Year Emissions: 2022 BMS Enterprise [1, 2]	Current Reporting Year Emissions: 2025 BMS Enterprise [1,2]
Total Scope 1	207,605	210,246 [3]
Scope 2 (Location Based)	119,782	120,791 [3]
Scope 2 (Market Based)	113,717	64,264 [3]
Total Scope 3	1,989,923	1,569,246

Category 1 - Purchased Goods and Services	1,494,301	1,137,857 [3,4,5]
Category 2 - Capital Goods	29,059	21,123 [3,4]
Category 3 - Fuel and Energy-Related Activities	72,778	70,964 [3]
Category 4 - Upstream Transportation and Distribution	182,142	121,335 [3,4,5]
Category 5 - Waste Generated in Operations	4,188	3,597 [3]
Category 6 - Business Travel	60,460	65,116 [3,6]
Category 7 - Employee Commuting/Work from Home	58,203	37,119 [3]
Category 9 - Downstream Transportation	3,746	2,376 [3]
Category 12 - End-of-Life Treatment of Sold Products	3,348	2,867 [3]
Category 15 - Investments	81,699	106,892 [3]
Total Value Chain (Scope 1, 2, & 3)	2,311,245	1,843,755

1. Totals may not equal the sum of individual values due to rounding of figures.
2. Due to the expanded boundary, totals include emissions data that has been estimated for facilities without activity data.
3. Metric included in 2025 External Data Assurance.
4. 2025 metric reflects a reduction in emissions due mainly to reduced year-over-year procurement spend.
5. 2025 metric reflects a reduction in emissions partially due to collection of activity data through supplier engagement and CDP Supply Chain responses.
6. 2025 metric reflects a reduction in emissions due to reduced commercial air travel.

Reduction targets and progress

			Progress Towards Goals
2028		Engage 75% of our suppliers by emissions[1] in their development of science-based and science-aligned targets	84%
2033		Reduce absolute Scope 1 and 2 GHG emissions 54.6% from a 2022 baseline year	27%
2033		Reduce absolute Scope 3 GHG emissions from fuel and energy-related activities (FERA) 54.6% by 2033 from a 2022 baseline year	5%
2050		Reach Net-Zero GHG emissions across our value chain	22%
2030		Procure 100% of purchased electricity from renewables	48%
2033		Reduce freshwater withdrawal by 20% from a 2024 baseline year	Goal introduced in 2026, progress will be updated in future reports
2040		Transform to 100% electric vehicles in our commercial fleet	5%
2040		Implement water stewardship across our operations	Aligned with AWS standards across our high water stress facilities.
2040		Achieve zero operational waste to landfill[2]	87%
	GOALS APPROVED BY THE SCIENCE BASED TARGETS INITIATIVE (SBTI)		

1. Covering purchased goods and services, capital goods and upstream transportation and distribution
2. Defined as 90% diversion rate across the facilities where we have activity data (estimated data not included)

Carbon Reduction Projects – 2025 Update

Supplier Engagement

Our Responsible Sourcing Program, launched in 2024, aims to monitor supplier or third-party sustainability risks while supporting suppliers through a journey of continuous improvement. We integrate environmental stewardship principles across our sourcing and procurement to

increase supplier due diligence and strengthen our overall approach to responsible supply chain management.

Our Supplier Decarbonisation Accelerator provides targeted resources and support for suppliers beginning their emissions tracking journeys. This programme takes a collaborative approach focused on engagement and education to provide resources and support to suppliers at all levels of climate maturity. Through roundtables, webinars, office hours and tailored resources such as white papers, we support suppliers in building capacity and collaborating on meaningful action on responsible environmental progress across our value chain.

BMS recognises that supply chain solutions vary in a complex, global supply chain, therefore we also collaborate with industry initiatives and collaborations that provide suppliers with additional resources and support:

- **Manufacture 2030 Program**: To accelerate environmental impact reduction across our Active Pharmaceutical Ingredients (API) suppliers, BMS co-founded, along with our peer companies, the Manufacture 2030 (M2030) activate programme. This initiative recognises that API production accounts for a significant proportion of the industry's carbon footprint and that our suppliers are at various stages of their sustainability journey. We seek to address this challenge by collaborating with our suppliers to align with science-based decarbonisation targets, drive sustainable procurement, and identify opportunities for operational and resource efficiency. As a participating pharmaceutical company, we also have access to the decarbonisation pathway projections of our API suppliers. This increased visibility will aid our own climate risk assessments, allow us to support our suppliers in meeting their climate targets, and strengthen the resilience of our value chain.
- **Energize**: Through Energize, suppliers gain free access to renewable energy procurement education and the ability to participate in multi-buyer power purchase agreements. By aggregating their power purchases, suppliers can gain access to long-term renewable energy deals that they may not have been able to commit to alone because of their limit. As our suppliers reduce their emissions by shifting to renewables, BMS reduces our Scope 3 emissions.
- **Converge**: BMS is a founding sponsor of the My Green Lab Converge programme, which unites leading pharmaceutical companies with suppliers to achieve measurable lab sustainability improvements through certification and shared accountability.
- **Pharmaceutical Supply Chain Initiative (PSCI)**: BMS is a full member of PSCI and co-leads the decarbonisation committee in its efforts to standardise industry-wide supplier solutions. Through the PSCI, we collaborate with peers and suppliers to discuss and share perspectives on environmental stewardship best practices.

Upstream Logistics

BMS strengthened our upstream transportation sustainability efforts in 2025 by transitioning from a set of discrete initiatives to a more structured, programmatic approach. Central to these efforts was launching the Sustainability Logistics Centre of Excellence (SCoE) to enhance governance and performance oversight for emissions reduction across upstream transportation logistics. The SCoE supports supplier engagement and alignment with recognised standards, including the GHG Protocol and Global Logistics Emissions Council Framework. As part of this, we developed a logistics Carbon Emissions Dashboard to provide

visibility into Scope 3 emissions from upstream transportation. The dashboard tracks emissions by lane, mode and supplier, identifying trends and hotspots across the logistics network. These insights support route optimisation and engagement with high-impact suppliers, while integrating emissions into regular performance reviews. To improve accuracy, we are transitioning to activity-based emissions reporting across our largest logistics partners, moving away from spend-based calculations. This strengthens our ability to identify efficiency opportunities aligned with operational realities.

As part of BMS's supplier engagement strategy, we worked collaboratively with European logistics partner H. Essers to embed sustainability expectations into logistics operations across 2024–2025. Together, we implemented a series of logistics optimisation initiatives designed to restructure how our medicines move through European supply chains. The partnership focused on addressing inefficiencies at their source, including partially loaded lorries, underutilised capacity and fragmented shipment patterns. These efforts reduced GHG emissions by eliminating non-optimised transport movements, consolidating shipments, deploying more efficient vehicles where possible and improving overall utilisation of shipping space. Without impacting service, the initiative yielded cost savings and emissions reductions during 2024-2025:

- 161 metric tonnes reduction in CO2e emissions
- 6%+ reduction in annual CO2 emissions 1K+ lorries fully optimised
- 35%+ increase in Less-than-Truck Load utilisation

Greener by Design

Our obligation to deliver safe, efficacious medicines requires rigorous microbial testing on injectable products. Historically, this process relied on an extract derived from horseshoe crab blood. Through rigorous evaluation of emerging innovations, BMS identified a science-powered synthetic alternative that maintains testing reliability equivalent or superior to that of horseshoe crab blood reagents. In keeping with our commitment to uncompromised product integrity and patient safety, we validated our use of the alternative to meet or exceed regulatory and quality standards. In 2025, BMS achieved significant progress in transitioning to the synthetic reagent, with reductions in our use of the animal-derived extract supporting the conservation of vulnerable horseshoe crab populations and the ecosystems they sustain. We are working to transition additional drug discovery facilities to the synthetic alternatives as we continue to expand the use of synthetic reagents for new medicines in our development pipeline. By reducing reliance on animal-derived reagents, we have decreased supply chain risks and strengthened our ability to adapt to evolving ecological and regulatory landscapes.

Our Base Metals Initiative helps us identify ways to replace expensive precious metals, such as palladium, with earth-abundant metals, such as cobalt and nickel, in chemical syntheses. To support these efforts, BMS has developed screening platforms to quickly identify reaction conditions with inexpensive nickel salts. This not only enables the replacement of palladium in individual chemical processes but also unlocks new starting materials and, in turn, new ways to make small molecules. Researchers from our Chemical Process Development team, working with the Keary Engle lab at the non-profit Scripps Research, were recognised with the 2025 ACS Green Challenge Award from the American Chemical Society and the ACS Green Chemistry Institute. The award honours their development of air-stable Nickel(0) catalysts for coupling reactions — a breakthrough that helps expand the use of base-metal catalysis

and supports more sustainable ways to manufacture drug substances. In 2025, we further strengthened our catalysis capabilities by concentrating on three core reaction types that together represent about 70% of the metal-catalysed chemistry in our portfolio. Through a collaboration with the Diao lab at New York University, we made meaningful progress in Suzuki cross-coupling, enabling us to evaluate when nickel can replace palladium without sacrificing reaction reliability or functional group compatibility.

Packaging

In 2025, we continued to make progress in sustainable packaging with a focus on reusable packaging systems for temperature-sensitive products and on eliminating or reducing packaging components. For temperature-sensitive products, we have increased our use of reusable thermal packaging systems that eliminate the need for new raw materials after each shipment, significantly reducing reliance on fossil fuel-based plastics and lowering landfill waste.

The below actions helped reduce waste to landfill in 2025:

- 66 metric tonnes by eliminating cotton from blood thinning medicine bottles for US patients.
- 18 metric tonnes through reduced sampling requirements for a biologic treatment for autoimmune disease.
- 2 metric tonnes by switching paper inserts to electronic versions for an immunotherapy treatment in Spain and Singapore.

Operational Energy Efficiency

Contributing to our near-term and net zero targets approved by the SBTi, we have an ambitious target to procure 100% renewable electricity in our operations by 2030. We expect to achieve our target by building on our current renewable energy portfolio and prioritising additionality of new renewables as our main strategy. We signed our first VPPA in 2021 for 60 megawatts (MW) at the Cattlemen Solar Park in Texas, which went live in 2024, Our second was signed in 2023 for 145 MW at the Blevins Solar Project Texas, which went live in April 2026. These two projects will account for 100% of our North American purchased electricity, which currently makes up more than three quarters of our global purchased electricity footprint. In 2025, our facilities in Germany, Ireland, Italy, the Netherlands and Switzerland all procured 100 per cent of their electricity from renewable sources.

In addition to purchased renewable energy, our solar photovoltaic (PV) footprint includes PV arrays installed in New Jersey locations and the United Kingdom. We are also focused on our commercial vehicles and the transformation to 100% EVs by 2040. To this end, we currently manage an on-site EV charging network across multiple facilities in the United States. We are enhancing energy efficiency across our operations, with initiatives like heat pump conversion, chiller plant optimisation and boiler upgrades, which have yielded energy and cost savings. Many of our energy efficiency and electrification initiatives also support nature resilience – co-benefits such as reducing cooling-related water demand and lowering upstream water and ecosystem impacts associated with fossil-based power generation are increasingly considered when prioritising investments.

Water Stewardship

In 2025 we completed two large projects:

- We upgraded equipment at our Lawrenceville, New Jersey, facility to improve how efficiently our cooling systems operate. By optimising heat transfer in our chillers, this upgrade is designed to reduce the amount of cooling water the facility needs and save approximately 10,000 cubic metres of water per year. This project demonstrates how technology upgrades can deliver significant water savings without disrupting operations.
- At our Princeton Pike, New Jersey, facility, we're capturing water that collects in the foundation drainage system and redirecting it to our cooling towers instead. This simple but effective reuse strategy will conserve a projected 10,000 cubic metres of freshwater each year while reducing treatment costs.

Waste

We strive to minimise waste across our global facilities and operations as we work towards our goal of zero waste to landfill by 2040.

Through partnerships with facility Environmental Health and Safety teams, suppliers, integrated facility management partners and organisations like My Green Labs, BMS advanced our zero operational waste to landfill initiative with new programmes and through the expansion of existing efforts:

- We launched a wood pallet recycling programme across select facilities to divert used or unwanted pallets from landfills.
- We established a lab plastics and amber bottle disposal diversion programme at our San Diego facility, transitioning materials from landfill to waste-to-energy.
- We grew our regulated medical waste recycling programme from three to six facilities, adding the New Brunswick, Cambridge Crossing and Warren facilities.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

Name: Annie ONG

Signature: 

Annie Ong (Aug 3, 2026 17:14:20 GMT+1)

Date: 03/08/2026